New opportunities explored for Freedom Leaf, Inc. to develop therapeutic nutraceutical cannabis/hemp products in the US and Internationally
LAS VEGAS, Nov. 28, 2016 /Weed Wire/ — Clifford J. Perry CEO of Freedom Leaf, Inc. “The Marijuana Legalization Company™” (OTC PINK: FRLF) announced today that Dr. Robert Melamede, Ph.D. and Dr. David J. Barton, MD are joining the company’s new medical advisory board.
Dr. Robert Melamede has a Ph.D. in Molecular Genetics and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he taught and researched cannabinoids, cancer, and DNA repair. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede, along with Richard C. Cowan, FRLF Chairman, co-founded Cannabis Science, Inc., the second publicly traded company in the cannabis sector, and he served as its CEO from 2008 to 2014.
Cowan said, “It is wonderful to have my old friend, ‘Dr. Bob,’ as he is known to so many admirers around the world, join us as we move forward.”
Dr. David J. Barton, MD is a clinician in Pain Medicine and a Medical Political Activist. He has been a physician for over 32 years. He is fellowship trained in Pain Medicine, and became board certified in Pain Medicine by the American Board of Pain Medicine in 2005. Past board certifications include General Surgery (1992) and Plastic Surgery (1995). Dr. Barton is a lifetime member of the American Society of Plastic Surgeons. Present member of the American Academy of Pain Medicine, the American Telemedicine Association, the International Cannabinoid Research Society, and the Hawaii Medical Association.
Dr. David J Barton served in the United States Army Reserve, General Surgeon, Medical Corp Officer, Major, 1990-1999, with temporary active duty in Desert Storm. Current volunteer Chief Medical Officer of Malama First, LLC; A non-profit organization for the enhancement of healthcare and well-being in Native Hawaiians.
Freedom Leaf, Inc., CEO Clifford J. Perry explained, “Freedom Leaf is honored to have these two distinguished scientists become the first members of our new Medical Advisory Board, as we explore the new opportunities for Freedom Leaf, Inc. to develop therapeutic and nutraceutical cannabis and hemp products in the US and internationally with our foreign licensees.”
Perry added, “Freedom Leaf, Inc. headquarters are in Las Vegas, where marijuana is now fully legal following the Nevada victory in the recent recreational initiative. With 8 states approving either medical or recreational or both on November 8th, there are now even more opportunities in other states that now either have medical and/or recreational marijuana laws or both. Internationally in Europe, Central and South America as well as Australia and Canada, we are seeing major accomplishments in the legality of marijuana which will create even more deal flow and revenue for Freedom Leaf, Inc. and our stockholders.”
About Freedom Leaf
Freedom Leaf, Inc., The Marijuana Legalization Company™, is a fully reporting and audited, publicly traded company trading under the symbol (OTC PINK: FRLF). Freedom Leaf, Inc. is the leading go-to resource in the cannabis, medical marijuana, and industrial hemp industry. It is involved in mergers and acquisitions in the marijuana industry, including incubation/acceleration and spin offs of new marijuana/hemp related companies.
Freedom Leaf Inc.‘s flagship publication is Freedom Leaf Magazine, The Good News in Marijuana Reform. The company produces a portfolio of news, print and digital multi-media verticals, websites, and web advertising, for the ever changing emerging cannabis, medical marijuana and industrial hemp industry. Freedom Leaf, Inc. does not handle, grow, sell, or disperse marijuana or related products.
Safe Harbor Statement
Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by phrases such as Freedom Leaf, Inc. or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, changes in relationships with third parties, and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K dated June 30, 2016 and quarterly reports on Form 10-Q.
Investor relations information can be found on the Freedom Leaf, Inc. website.
PR and Business Development Director
Freedom Leaf, Inc.
3571 East Sunset Road
Las Vegas, Nevada 89120